Increased exposure w/ CYP450, UGT1A1 & 1A9, P-gp/BCRP eg, ketoconazole, itraconazole & HIV PIs eg, ritonavir. Potentiated blood lowering effect of SL nitroglycerin. Additive systemic BP lowering effect w/ sildenafil or vardenafil. Caution w/ cyclosporine A. Lowered oral bioavailability w/ drugs increasing upper GI pH. Reduced mean AUC & C
max by antacids eg, Al & Mg hydroxide. Decreased steady-state plasma conc by bosentan & strong CYP3A4 inducers eg, phenytoin, carbamazepine, phenobarb or St. John's wort.